85 search results for: patient burden

The Prevalence and <b>Burden</b> of Type 2 Inflammation in <b>Patient</b>s With CRSwNP

expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

8 min

Rhinology

Dr. Stella Lee educates on the immune responses mediating CRSwNP and the prevalence of type 2 inflammation.

expert video

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

16 min

Dermatology

Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema

IRS-ISIAN 2024 | The Underappreciated <b>Burden</b> of Smell Loss and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

7 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

CRSwNP Significantly Affects the Quality of Life of CRSwNP <b>Patient</b>s

interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

10 min

Rhinology

Explore the factors that contribute to the significant burden of CRSwNP on patient quality of life.

Importance of Lung Function Assessment in Pediatric Asthma <b>Patient</b>s

videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

3 min

Pulmonology

Review the burden associated with lung function decline in pediatric patients with severe asthma, and the value of clinical lung function assessments.

expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

42 min

Pulmonology

Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

Type 2 Inflammation Mediates Severe Asthma in Pediatric <b>Patient</b>s

expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min

Pulmonology

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

The Impact of Skin Fibrosis in <b>Patient</b>s with Prurigo Nodularis

videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

3 min

Dermatology

An animated infographic exploring the patient burden and pathophysiology of skin fibrosis in prurigo nodularis, specifically detailing how fibrotic pathways are driven and the key molecules involved.

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for <b>Patient</b>s?

Podcast

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

20 min

Dermatology

This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.

ADVENT On Air | Defining AD in Pediatric <b>Patient</b>s

Podcast

ADVENT On Air | Defining AD in Pediatric Patients

15 min

Dermatology

Learn more about the journey of pediatric patients with AD in this conversation between Drs. Lisa Swanson and Weily Soong.

Importance of Lung Function Assessment in Adult Asthma <b>Patient</b>s

videoanimation

Importance of Lung Function Assessment in Adult Asthma Patients

3 min

Pulmonology

Review the burden associated with lung function decline in adult patients with severe asthma, and the value of clinical lung function assessments.

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South KoreaChange country/region